Background: In 2021, the European Union reported >270,000 excess deaths, including >16,000 in Portugal. The Portuguese Directorate-General of Health developed a deep neural network, AUTOCOD, which determines the primary causes of death by analyzing the free text of physicians' death certificates (DCs). Although AUTOCOD's performance has been established, it remains unclear whether its performance remains consistent over time, particularly during periods of excess mortality.
Objective: This study aims to assess the sensitivity and other performance metrics of AUTOCOD in classifying underlying causes of death compared with manual coding to identify specific causes of death during periods of excess mortality.
Methods: We included all DCs between 2016 and 2019. AUTOCOD's performance was evaluated by calculating various performance metrics, such as sensitivity, specificity, positive predictive value (PPV), and F-score, using a confusion matrix. This compared International Statistical Classification of Diseases and Health-Related Problems, 10th Revision (ICD-10), classifications of DCs by AUTOCOD with those by human coders at the Directorate-General of Health (gold standard). Subsequently, we compared periods without excess mortality with periods of excess, severe, and extreme excess mortality. We defined excess mortality as 2 consecutive days with a Z score above the 95% baseline limit, severe excess mortality as 2 consecutive days with a Z score >4 SDs, and extreme excess mortality as 2 consecutive days with a Z score >6 SDs. Finally, we repeated the analyses for the 3 most common ICD-10 chapters focusing on block-level classification.
Results: We analyzed a large data set comprising 330,098 DCs classified by both human coders and AUTOCOD. AUTOCOD demonstrated high sensitivity (≥0.75) for 10 ICD-10 chapters examined, with values surpassing 0.90 for the more prevalent chapters (chapter II-"Neoplasms," chapter IX-"Diseases of the circulatory system," and chapter X-"Diseases of the respiratory system"), accounting for 67.69% (223,459/330,098) of all human-coded causes of death. No substantial differences were observed in these high-sensitivity values when comparing periods without excess mortality with periods of excess, severe, and extreme excess mortality. The same holds for specificity, which exceeded 0.96 for all chapters examined, and for PPV, which surpassed 0.75 in 9 chapters, including the more prevalent ones. When considering block classification within the 3 most common ICD-10 chapters, AUTOCOD maintained a high performance, demonstrating high sensitivity (≥0.75) for 13 ICD-10 blocks, high PPV for 9 blocks, and specificity of >0.98 in all blocks, with no significant differences between periods without excess mortality and those with excess mortality.
Conclusions: Our findings indicate that, during periods of excess and extreme excess mortality, AUTOCOD's performance remains unaffected by potential text quality degradation because of pressure on health services. Consequently, AUTOCOD can be dependably used for real-time cause-specific mortality surveillance even in extreme excess mortality situations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11041420 | PMC |
http://dx.doi.org/10.2196/40965 | DOI Listing |
Background: Alzheimer's disease (AD) agitation is a distressing neuropsychiatric symptom characterized by excessive motor activity, verbal aggression, or physical aggression. Agitation is one of the causes of caregiver distress, increased morbidity and mortality, and early institutionalization in patients with AD. Current medications used for the management of agitation have modest efficacy and have substantial side effects.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Karolinska Institute, Stockholm, Södermanland and Uppland, Sweden.
Background: Novel anti-amyloid therapies (AAT) for Alzheimer's Disease (AD) have recently been approved in the United States, Japan and China, and are under regulatory review in Europe. Questions remain regarding the long-term effectiveness and value of these drugs when used in routine clinical practice. Data from follow-up studies will be important to inform their optimal use, including criteria for treatment initiation, monitoring strategies, stopping rules, pricing and reimbursement considerations.
View Article and Find Full Text PDFBackground: Seizures in Alzheimer's Disease (AD) are increasingly recognized to occur and can increase cognitive decline and reduce survival compared to unaffected age-matched peers (Lyou et al. 2018). Administration of antiseizure medicines (ASMs) to AD patients with epileptiform activity may improve cognition (Vossel et al.
View Article and Find Full Text PDFClin Appl Thromb Hemost
January 2025
Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Deep vein thrombosis (DVT) is a leading cause of death disability. DVT can be classified based on the location and extent of the clot into isolated distal DVT (iDDVT), isolated proximal DVT (iPDVT), or mixed DVT. The aim of this study is to explore the baseline characteristics and clinical outcomes of patients with different types of DVT.
View Article and Find Full Text PDFBackground: The new anti-Aβ antibody drugs aducanumab and lecanemab (approved in the US, not yet in Europe) must be followed up closely and regularly long-term. Previous knowledge on progression of AD in routine clinical settings longterm is crucial when introducing new dementia medications. The Swedish national quality database on dementia/cognitive disorders, SveDem, where data on different dementia disorders at the time of the dementia diagnosis since 2007 and on mild cognitive impairment (MCI) since 2021 with annual follow-ups of MMSE scores can provide this unique information.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!